Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Harm Reduction Program For Informal PrEP Users In A Community-based Setting (seguiPrEP) (seguiPrEP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03996941
Recruitment Status : Recruiting
First Posted : June 25, 2019
Last Update Posted : July 9, 2019
Sponsor:
Collaborators:
Projecte dels NOMS-Hispanosida (BCN Checkpoint and BCN PrEP·Point)
Fundacio Lluita Contra la SIDA
Information provided by (Responsible Party):
BCN Checkpoint

Brief Summary:

Pre-Exposure Prophylaxis (PrEP) is a biomedical strategy consisting of the use of antiretroviral therapy by HIV-seronegative people at high risk of acquiring HIV, to prevent the infection. Many controlled and randomized clinical trials, as well as implementation projects have shown that the use of tenofovir disoproxil (TDF) and emtricitabine (FTC) is both safe and effective in the prevention of HIV infection.

However, the administrative situation of PrEP in Spain is anomalous. Unlike in some European countries, PrEP is not available within the National Health System (SNS), although being available for the treatment of HIV infection. In Spain the fixed-dose combination of FTC / TDF is for hospital use only, which requires prescription by HIV specialists exclusively and restricts its dispensation to pharmacy services within the hospital.

This limitation in access and the knowledge of its prevention capacity of PrEP by vulnerable population has led them to obtain "generic FTC / TDF" outside the standardized health care system. According to a survey conducted in Europe to characterize MSM users of PrEP carried out in 2016, 5% of PrEP users had acquired it on their own. Of these 70% stated they were not included in any regular follow-up program while using the medication. Despite the growing demand, there are no health programs (including information, counseling, systematic screening for sexually transmissible infection (STI), etc.) aimed at meeting the health care needs of those who already use or wish to use PrEP, neither by public nor private healthcare providers. This type of service is especially necessary when considering that, among PrEP users, one may have already an established HIV infection, theoretical increase of other STI and a lack of monitoring kidney functions..

BCN Checkpoint is a community center since 2006 for the detection of HIV and other STI aimed at gay men, other men who have sex with men (MSM) and transgender women (TGW), which has shown high efficiency in HIV screening and fast referral to standard HIV care and treatment.. In 2017 the organization opened BCN PrEP·Point, a community centre with the goal to provide information, to conduct clinical trials and clinical monitoring of informal PrEP use.

For this reason, it is presented here the protocol of the SeguiPrEP study, prospective, longitudinal study of health care in the community environment, to MSM and TGW, users of informal PrEP, based on point-of-care testing technology.


Condition or disease Intervention/treatment
HIV/AIDS HIV Infections Sexually Transmitted Diseases Vaccination Adherence, Medication Side Effect of Drug Preexposure Prophylaxis Behavioral: Harm reduction of informal PrEP use Other: PrEP follow up based on point of care testing

Detailed Description:

In Catalonia 62% of new HIV diagnoses were reported in MSM in 2017. In the decade 2007-2016 in this population group an increase in the number of HIV cases of approximately 44%. The knowledge, interest and willingness to use PrEP is high among MSM at higher risk of HIV acquisition. BCN Checkpoint was accountable for the detection of one third of all new HIV cases in MSM and TGW in Catalonia.

Research hypothesis is that offering a risk reduction program, including the provision of health monitoring, in a community setting for informal PrEP users is justified and feasible, and will afford these users the possibility of using it safely. It is expected that the use of informal PrEP, along with HIV and other STIs screening, STI treatment, and immediate HIV referral to care and treatment will contribute significantly to a reduction of HIV incidence.

This study aims to contribute to increase the body of evidence on the incidence and of context specific HIV management and inform policy makers on potential preventive strategies against the epidemic.

AIMS

The primary aim of the study is:

To describe the incidence of HIV and other STIs during the study period.

The specific aims of the study are:

To provide harm reduction through clinical follow-up for informal PrEP users. To describe the conditions of informal use and acquisition of PrEP. To evaluate the effectiveness and safety of informal PrEP. To describe the demographic, clinical, risk factors for HIV and other STIs of informal PrEP users.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 900 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Harm Reduction Program For Informal PrEP Users In A Community-based Setting
Actual Study Start Date : July 5, 2019
Estimated Primary Completion Date : September 1, 2024
Estimated Study Completion Date : September 1, 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Group/Cohort Intervention/treatment
seguiPrEP
MSM and TGW using or willing to use PrEP informally will be followed in a prospective cohort to describe safety and efficacy, and to provide them with the necessary clinical controls for using it in a safe manner.
Behavioral: Harm reduction of informal PrEP use

Users attending the study center interested in PrEP use , as well as those who could benefit from it are invited to attend an information session in which issues are touched like the effectiveness and safety of PrEP, and the characteristics of the SeguiPrEP program. This program consists of periodic clinical controls (five during the first year and four in the following period) that include: physical examination, HIV and other STI screening, control of renal functions, estimation and promotion of PrEP adherence, monitoring of adverse events associated with PrEP and counseling.

Those who decide to use PrEP or who are already using PrEP are asked to schedule an initiation visit.


Other: PrEP follow up based on point of care testing
The study center has a point-of-care technology based laboratory, which allows obtaining immediate results in order to reduce the loss of follow-up.




Primary Outcome Measures :
  1. Incidence of HIV and other STIs during the study period. [ Time Frame: 36 months ]

Secondary Outcome Measures :
  1. Number of people / visits = Number of visits / people who attend any visit [ Time Frame: 36 months ]

    This indicator will be calculated for both the number of visits and the number of people.

    Disaggregation: based on sociodemographic characteristics and type of visit and PrEP guidelines


  2. Retention percentage in the program [ Time Frame: 36 months ]
    % retention in the program = (People who complete the study as per protocol) / (People enrolled) x100 Disaggregation: based on sociodemographic characteristics, presence of other STIs, use of drugs and number of sexual partners.

  3. Number of medicines-related problems [ Time Frame: 36 months ]
    Number of problems = Number of medicines-related problems Disaggregation:based on type of problem as per protocol, sociodemographic characteristics, use of drugs, medication, way of acquisition and other relevant factors

  4. Number of negative results of the medication [ Time Frame: 36 months ]
    Number of negative results of the medication = Number of negative results of the medication Disaggregation: based on type of negative result as per protocol, sociodemographic characteristics, drug use, medication, way of acquisition and other relevant factors



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Study is addressed to men who have sex with men and transgender women
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Potential participants will be those who report using or intend to use PrEP, attending the community centers on a regular or spontaneous basis. Potential participants may be recruited for the study if they meet all inclusion criteria.
Criteria

Inclusion Criteria:

  • At least 18 yo at the time of the enrollment in the study.
  • Accept voluntarily participation through signing informed consent, once explained its characteristics.
  • Have obtained recently (less than 1 month) a negative result in the combined antigen/antibody rapid test / 4th generation ELISA or PCR HIV test.
  • Active user or intending to use informal PrEP.

Exclusion Criteria:

  • People with known HIV diagnosis.
  • Absolute contraindication (eg known hypersensitivity to the active ingredients FTC or TDF) of the use of PrEP.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03996941


Contacts
Layout table for location contacts
Contact: Pep Coll, MD 933182056 info@hispanosida.com

Locations
Layout table for location information
Spain
BCN Checkpoint Recruiting
Barcelona, Spain, 08015
Contact    933182056      
Sponsors and Collaborators
BCN Checkpoint
Projecte dels NOMS-Hispanosida (BCN Checkpoint and BCN PrEP·Point)
Fundacio Lluita Contra la SIDA
Investigators
Layout table for investigator information
Principal Investigator: Pep Coll, MD Fundación Lucha contra el Sida
Additional Information:
Layout table for additonal information
Responsible Party: BCN Checkpoint
ClinicalTrials.gov Identifier: NCT03996941    
Other Study ID Numbers: BCP-FTD-2019-01
First Posted: June 25, 2019    Key Record Dates
Last Update Posted: July 9, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by BCN Checkpoint:
PrEP
Community setting
point of care
Additional relevant MeSH terms:
Layout table for MeSH terms
Sexually Transmitted Diseases
Drug-Related Side Effects and Adverse Reactions
Virus Diseases
Infection
Genital Diseases, Male
Genital Diseases, Female
Chemically-Induced Disorders